Advertisement

Topics

Latest "Dexamethasone Therapy in VLBW Infants at Risk of CLD" News Stories

18:47 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Dexamethasone Therapy in VLBW Infants at Risk of CLD" found in our extensive news archives from over 250 global news sources.

More Information about Dexamethasone Therapy in VLBW Infants at Risk of CLD on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Dexamethasone Therapy in VLBW Infants at Risk of CLD for you to read. Along with our medical data and news we also list Dexamethasone Therapy in VLBW Infants at Risk of CLD Clinical Trials, which are updated daily. BioPortfolio also has a large database of Dexamethasone Therapy in VLBW Infants at Risk of CLD Companies for you to search.

Showing "Dexamethasone Therapy VLBW Infants Risk" News Articles 1–25 of 17,000+

Tuesday 26th March 2019

AdventHealth Zephyrhills Receives Cuddle Cot Donation for Grieving Families

Local husband and wife who lost their son at birth plan six Cuddle Cot donations throughout the U.S. ZEPHYRHILLS, Fla. (PRWEB) March 26, 2019 The family of Collin Sebastian Mellor has partnered with Madison’s Miracles to graciously donate a Cuddle Cot to The Baby Place® at AdventHealth Zephyrhills, in honor of their son. Collin Sebastian Mellor passed away September 1, 2018 during birth at...


Greenberg Traurig’s Evan Holden Speaks at National Academy of Sciences Roundtable on Biomedical Engineering Materials Applications

Evan Holden, a shareholder in the Atlanta office of global law firm Greenberg Traurig, LLP, was a panelist at the National Academy of Sciences (NAS) Roundtable on Biomedical Engineering Materials Applications (BEMA) March 25 in Washington D.C. at NAS’ Keck Center. ATLANTA (PRWEB) March 26, 2019 Evan Holden, a shareholder in the Atlanta office of global law firm Greenberg Traurig, LLP, was a pan...

Baxter Highlights Advancements in Clinical Nutrition at ASPEN Conference

Reinforces the company’s efforts to innovate nutrition formulations and delivery mechanisms to meet the needs of patients Baxter International Inc. (NYSE:BAX), a global leader in clinical nutrition, today announced it will launch Clinolipid (20% Lipid Injectable Emulsion), its proprietary olive oil-based lipid emulsion, in the U.S. later this year ...


Anti-TB Drugs Can Increase Risk of TB Re-infection

NewsCurrent treatments for tuberculosis are very effective in controlling TB infection. They don't, however, always prevent reinfection.Contributed Auth

FDA Approval Sought for Frontline Daratumumab Regimen in Transplant-Eligible Myeloma

A supplemental biologics license application has been submitted to the FDA for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Triplex Meets Primary Endpoint in Phase 2 Clinical Trial, Reduces Rate of Cytomegalovirus (CMV) Complications in Transplant Recipients by 50 Percent

First prophylactic vaccine to demonstrate proof of concept for CMV control independent of human leukocyte antigen (HLA) status in stem cell transplant recipients City of Hope, a world-renowned cancer research and treatment center, announced today that Triplex has met its primary endpoint (reduction of CMV events) in a

Pulse Biosciences Announces Presentations at the 2019 American Society for Laser Medicine and Surgery Annual Conference

Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that key findings from its clinical programs using Nano-Pulse Stimulation™ (NPS™) technology will be presented at the American Society for Laser Medicine and Surgery’s (ASLMS) Annual Conference being held March 27-31, ...

Your NEJM Group Today: Hand & Wrist Exam Video / Spinal Manipulative Therapy & Low Back Pain / Nephrology & Geriatrics Opportunities

Take a peek at today's top picks from NEJM Group: NEJM Primary Care/Hospitalist Page: Videos in Clinical Medicine: This video describes the anatomy of...

CDC Calls on Clinicians, Health Departments to Control Hepatitis A Outbreaks

The CDC is calling for a rapid public health response to help stem the rash of hepatitis A outbreaks among high-risk groups across the...

Aimmune's peanut allergy therapy closes in on approval with promising Phase 3 data http://bit.ly/2URxTUW  #PeanutAllergy @aimmune #pharma

Aimmune's peanut allergy therapy closes in on approval with promising Phase 3 data http://bit.ly/2URxTUW  #PeanutAllergy @aimmune #pharma

Roche quietly discontinues Ignyta cancer therapy RXDX-105

Roche’s RXDX-105, which was being developed by Ignyta, has had its development discontinued, according to an industry source. The move...Read More... The post Roche quietly discontinues Ignyta cancer therapy RXDX-105 appeared first on Pharmaceutical Technology.

Nexstim Plc: Nexstim Plc publishes prospectus regarding EUR 5.2 million rights issue and new information regarding previous profit forecast

Company announcement, Helsinki, 26 March 2019 at 6.00 PM Nexstim Plc: Nexstim Plc publishes prospectus regarding EUR 5.2 million rights issue and new information regarding previous profit forecastNexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-inva...

Orion Corporation: Organising meeting of the Board of Directors

 Orion Corporation                                Stock Exchange Release  26 March 2019 at 5.30 p.m. EET Orion Corporation: Organising meeting of the Board of Directors In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Timo Maasilta as Vice ...

Midlife Diet and Dementia Risk: A Negative Study

Midlife diet was not associated with risk for dementia during >10 years of follow-up.

Childhood Cancer Survivors at Increased Risk for Skin Cancers

Childhood cancer survivors who had lived 5 or more years from their primary malignancy are at an increased risk of developing skin cancer compared with the general population.

Jump Technologies, X3 Consulting Group Announce Partnership to Streamline Supply Chain Process and Mitigate Risk for Hospitals

New X3 Operating Guide offers shared-risk model that reduces waste and increases revenue from lost charge capture for hospitals, while enabling nurses to spend more time on patient care EAGAN, Minn. (PRWEB) March 26, 2019 A new strategic alliance between Jump Technologies and X3 Consulting Group (X3) has the potential to capture missed hospital revenues from ORs (operating rooms) and procedure su...

Promedior Receives Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., March 26, 2019 /PRNewswire/ — Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that PRM-151, a novel investigational anti-fibrotic immunomodulator, has been granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for Idiopathic Pulmonary Fibrosis (IPF).&...

Virginia Tech Launches Clinical Trial for Rehabilitating Infant Stroke Victims

Senior therapist Mary Rebekah Trucks in a rehabilitation session with a young patient Virginia Tech, today announced the launch of the nation’s first multicenter pediatric stroke recovery trial for researchers and clinicians from 12 sites across the United States will evaluate an innovative therapeutic approach to help 8-month-old to 24-month-old infants. Named The clinical trial ... Read Mo...

Thermo Fisher Expands Gene Therapy Business with $1.7 Billion Acquisition of Brammer Bio

WALTHAM, Mass. and CAMBRIDGE, Mass., March 24, 2019 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, today announced they have entered into a definitive agreement under which Thermo Fisher will acquire Brammer Bio for approximately …

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism

Impact on patient quality of life quantified including long-term renal and cardiovascular complications Final outcomes of 6 year study into continuous use of rhPTH(1-84) shows improvements in key measurements of mineral homeostasis Takeda Pharmaceutical Company Limited (

Biotech bluebird opens $80 million gene therapy complex

The company purchased the 125,000-square-foot manufacturing facility, located in Durham, North Carolina, in November 2017

Pall agrees to develop New Jersey cell and gene therapy sites

Pall Biotech signs an industry participation agreement with the New Jersey Innovation Institute to create two centres designed to develop and manufacture cell and gene therapies.

Spinal Manipulative Therapy for Chronic Low Back Pain

SMT provided similar pain relief and improved function compared with recommended therapies.

Move More, Live Longer

TUESDAY, March 26, 2019 -- If you're a couch potato, get moving. Your life could depend on it. Researchers say replacing 30 minutes a day of sitting with physical activity could cut your risk of premature death by nearly half. They examined 14 years...

Japan approvals include Kymriah as Japan's first CAR T therapy


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks